| Outcome Measures: |
Primary: Systolic blood pressure, SBP, Change from baseline systolic blood pressure (SBP) at 12 weeks of treatment | Secondary: Fasting plasma glucose, Fasting plasma glucose, Change from baseline fasting plasma glucose at 12 weeks of treatment|HbA1c, HbA1c, Change from baseline HbA1c at 12 weeks of treatment|Continuous home glucose monitoring, Continuous home glucose monitoring, Continuous glucose will be monitored for 14 days at 2 time intervals: 7 days prior to 7 days after drug administration (week -1 to1) and 7 days prior to 7 days after during drug discontinuation (week 11 to 13)|Arterial stiffness, Measured using a Sphygmocor device, Change from baseline arterial stiffness at 12 weeks of treatment|Systemic vascular resistance, Measured using non-invasive cardiac output monitor (NICOM), Change from baseline systemic vascular resistance at 12 weeks of treatment|Glomerular Filtration Rate, GFR, Change from baseline GFR (based on plasma iohexol clearance) at 12 weeks of treatment|Estimated Glomerular Filtration Rate, eGFR, Change from baseline eGFR (based on CKD-EPI equation) at 12 weeks of treatment|Proximal tubular natriuresis, Measured by fractional excretion of sodium and 24-hour urine collection, Change from baseline proximal tubular natriuresis at 12 weeks of treatment|Albuminuria, Albuminuria, Change from baseline albuminuria at 12 weeks of treatment|Urinary and plasma concentration of oxidative stress markers, Measured using ELISA, Change from baseline oxidative stress markers at 12 weeks of treatment|Tubulointerstitial hypoxia, Measured using a renal ultrasound (photoacoustic ultrasonography), Change from baseline tubulointerstitial hypoxia at 12 weeks of treatment|Calcineurin inhibitor (CNI) Levels, CNI, Change from baseline CNI at 12 weeks of treatment|Adverse Events (AEs), AEs, Adverse events will be recorded from baseline throughout the study duration up to 13 weeks
|
